Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Multicenter, Open Label Study of Enadenotucirev Combined With PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors

NCT02636036 is registered in ClinicalTrials.gov with Akamis Bio as lead sponsor.

NCT NCT02636036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02636036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Multicenter, Open Label Study of Enadenotucirev Combined With PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors
Lead sponsor
Akamis Bio
Phase
Phase 1
Overall status
Completed
Start date
January 25, 2016
Completion date
October 8, 2021
Enrollment
51 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, epithelial tumor, squamous cell carcinoma of the head and neck